Pasar al contenido principal

NUEVAS ESTRATEGIAS BASADAS EN DC PARA POTENCIAR LA IMMUNOTERAPIAS CON CELULAS T CD8+ Y CELULAS NK CITOTOXICAS CONTRA EL RESERVORIO LATENTE DE VIH

RTI2018-097485-A-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Combined dendritic cell and anti-TIGIT immunotherapy potentiates adaptive NK cells against HIV-1

  • Sánchez-Cerrillo, Ildefonso
  • Agudo-Lera, María
  • Popova, Olga
  • Tsukalov, Ilya
  • Calvet-Mirabent, Marta
  • de los Santos, Ignacio
  • García-Fraile, Lucio
  • Fuentes, Patricia
  • Delgado-Arévalo, Cristina
  • Alcain, Juan
  • Sánchez-Gaona, Nerea
  • Grau-Expósito, Judith
  • Lázaro-Díez, María
  • Muñoz-Calleja, Cecilia
  • Alfranca, Arantzazu
  • Genescà, Meritxell
  • Prado, Julia G.
  • Vrbanac, Vladimir
  • Balazs, Alejandro
  • Buzón, María José
  • Toribio, María L.
  • Muñoz-Fernández, María A.
  • Sánchez-Madrid, Francisco
  • Martín-Gayo, Enrique
Natural Killer (NK) cells are promising candidates for targeting persistently infected CD4 + T cells in people with HIV-1 (PWH). However, chronicity of HIV-1 infection impairs NK cell functionality, requiring additional strategies to potentiate their cytotoxic activity. This study demonstrates that dendritic cells primed with nanoparticles containing Poly I:C (Nano-PIC-MDDC) enhance the natural cytotoxic function of NK cells from effective responder PWH. These NK cells exhibit increased proportions of NKG2C+ cell subsets capable of eliminating HIV-1 infected CD4 + T cells through the TRAIL receptor. In contrast, in non-responder PWH, elevated expression of the inhibitory receptor TIGIT is associated with reduced frequencies of NKG2C + NK cells and diminished TRAIL expression. TIGIT blockade restores cytotoxicity of NK cells from non-responder PWH against HIV-1-infected cells by upregulating TRAIL. Furthermore, combining Nano-PIC-MDDC-primed NK cells with anti-TIGIT immunotherapy in humanized NSG mice reduces the expansion of HIV-1 infected cells, preserves NKG2C + NK cell precursors and increases TRAIL expression in tissue. Collectively, these findings support the combined use of Nano-PIC-MDDC and TIGIT blockade as a promising immunotherapeutic strategy toward an HIV-1 cure., EMG was supported by Ramón y Cajal Program (RYC2018-024374-I), the Spanish Agencia Estatal de Investigación RETOS, Generación de conocimiento and consolidation programs (RTI2018-097485-A-I00; PID2021-127899OB-I00; CNS2023-144841), La Caixa Banking Foundation ETI-CureHIV (HR20-00218), GLD24/00117 grant from Gilead Biosciences and infectious diseases CIBER (CIBERINFEC) from ISCIII (CB21/13/00107). MAL was supported by the Formación de Personal Investigador (FPI) grant PRE2022-104516. IT was supported by FPI UAM fellowship. CDA was supported by Comunidad de Madrid Talento Program (2017-T1/BMD-5396). MCM was supported by La Caixa Foundation ETI-CureHIV (HR20-00218). P2022/BMD7209-INTEGRAMUNE from Comunidad Autónoma de Madrid and La Caixa Health Research Grant LCF/PR/HR23/52430018 to and PID2023-149541OB-I00 FSM also supported the study. ISC was supported by infectious diseases CIBER from ISCIII (CB21/13/00107). JGP was supported by La Caixa Health program ETI-CureHIV project (HR20-00218), the CIBERINFECC from the National Health Institute Carlos III, and the project PI22/01120. MLT was supported by the Spanish Agencia Estatal de Investigación, Ministerio de Ciencia, Innovación y Universidades (PID2022-138880OB-I00 and PDC2021-121238-I00). NMC contributed to ROC Curve analysis.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

ISG15 modulates inflammatory profiles and ability to activate CD8 + T cells in bone marrow-derived dendritic cells

  • Martínez-Fleta, Pedro
  • Pertusa, Clara
  • Fernández-Delgado, Irene
  • Izquierdo-Serrano, Raúl
  • Ramírez-Huesca, Marta
  • Fernández-Gallego, Nieves
  • Calzada-Fraile, Diego
  • Moya-Ruiz, Elena
  • Castillo-González, Raquel
  • Guerra, Susana
  • Martín-Gayo, Enrique
  • Sánchez-Madrid, Francisco
The Interferon-Stimulated Gene 15 (ISG15) has a key role during viral infections, since it can modify and regulate the expression of proteins from the host and from viruses. Isg15 mice are more susceptible to infectious diseases. ISG15 is induced by type I Interferons (IFN-I) and apart from defense against pathogens, it can also play an important function in cancer or immune-mediated inflammatory diseases. Previous studies reported that ISG15 expression is increased in post-synaptic dendritic cells (DCs) upon interaction with CD4 + T cells. However, data regarding the role of ISG15 in DCs are scarce. The present study assesses the function of ISG15 in DCs activation, migration and ability to mediate T cell activation using bone marrow-derived DCs (BMDCs) and stimulation with lipopolysaccharide (LPS). Activation of DCs was not impaired but tended to be lower in Isg15-deficient mice, as observed by reduced CD40 induction in Isg15 BMDCs. Isg15 BMDCs induced less proliferation and Granzyme B expression in co-cultured CD8 + T cells. Interestingly, Isg15 BMDCs secreted reduced levels of the pro-inflammatory cytokines IL-1β and IL-12 upon LPS stimulation. Mechanistically, our data suggest that ISG15 regulates Caspase-1 activity in DCs leading to lower IL-1 β secretion. In conclusion, this study reveals an essential role for ISG15 modulating DCs inflammatory activity and raises new questions regarding the specific mechanisms of how this protein regulates innate immune responses., F.S.-M.’s laboratory is funded by the Spanish Ministry of Science and Innovation, Agencia Estatal de Investigación grants PID-2020-120412RB-I00, PID2023-149541OB-I00, “La Caixa” Foundation project code LCF/PR/HR23/52430018, P2022/BMD7209 (INTEGRAMUNE) funded by Comunidad de Madrid, and a grant from the Asociación Española Contra el Cáncer (AECC; PRYCO223002PEIN). E.M.-G. was supported by the Spanish Agencia Estatal de Investigación RETOS, Generación de conocimiento and consolidation programs (RTI2018-097485-A-I00;PID2021-127899OB-I00; CNS2023-144841), La Caixa Banking Fundation ETI-CureHIV(HR20-00218) and infectious diseases CIBER from ISCIII (CIBERINFEC) and a Gilead grant (GLD24/00117). R.C.-G. is supported by Ayudas para contratos Juan de la Cierva-formación 2021 (FJC2021-047282-I) from MICIN (Spain). P.M.-F. has been funded by a Rio-Hortega grant CM22/00076 from the Ministerio de Ciencia e Innovación (Instituto de Salud Carlos III) and co-funded by the European Regional Development Fund (ERDF) “A way to make Europe”. R.I.-S. was supported by a grant from the Spanish Agencia Estatal de Investigación (Ministerio de Ciencia e Innovación) (PRE2020-091912). E.M.-R. was supported by a grant from Comunidad de Madrid and co-funded by the European Regional Development Fund (ERDF) “A way to make Europe”. Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Antiretroviral therapy duration and immunometabolic state determine efficacy of ex vivo dendritic cell-based treatment restoring functional HIV-specific CD8+ T cells in people living with HIV

  • Calvet-Mirabent, Marta|||0000-0002-9134-0849
  • Sánchez Cerrillo, Ildefonso
  • Martín-Cófreces, Noa
  • Martínez-Fleta, Pedro
  • Fuente, Hortensia de la
  • Tsukalov, Ilya
  • Delgado-Arévalo, Cristina
  • Calzada, María José
  • de los Santos Gil, Ignacio|||0000-0001-7073-5211
  • Sanz, Jesús
  • García-Fraile Fraile, Lucio|||0000-0002-2512-6107
  • Sánchez-Madrid, Francisco|||0000-0001-5303-0762
  • Alfranca, Arantzazu|||0000-0002-3732-5816
  • Muñoz Fernández, María Ángeles
  • Buzón, Maria José|||0000-0003-4427-9413
  • Martín-Gayo, Enrique
Dysfunction of CD8 + T cells in people living with HIV-1 (PLWH) receiving anti-retroviral therapy (ART) has restricted the efficacy of dendritic cell (DC)-based immunotherapies against HIV-1. Heterogeneous immune exhaustion and metabolic states of CD8 + T cells might differentially associate with dysfunction. However, specific parameters associated to functional restoration of CD8 + T cells after DC treatment have not been investigated. We studied association of restoration of functional HIV-1-specific CD8 + T cell responses after stimulation with Gag-adjuvant-primed DC with ART duration, exhaustion, metabolic and memory cell subsets profiles. HIV-1-specific CD8 + T cell responses from a larger proportion of PLWH on long-term ART (more than 10 years; LT-ARTp) improved polyfunctionality and capacity to eliminate autologous p24 + infected CD4 + T cells in vitro. In contrast, functional improvement of CD8 + T cells from PLWH on short-term ART (less than a decade; ST-ARTp) after DC treatment was limited. This was associated with lower frequencies of central memory CD8 + T cells, increased co-expression of PD1 and TIGIT and reduced mitochondrial respiration and glycolysis induction upon TCR activation. In contrast, CD8 + T cells from LT-ARTp showed increased frequencies of TIM3 + PD1 - cells and preserved induction of glycolysis. Treatment of dysfunctional CD8 + T cells from ST-ARTp with combined anti-PD1 and anti-TIGIT antibodies plus a glycolysis promoting drug restored their ability to eliminate infected CD4 + T cells. Together, our study identifies specific immunometabolic parameters for different PLWH subgroups potentially useful for future personalized DC-based HIV-1 vaccines. NIH (R21AI140930), MINECO/FEDER RETOS (RTI2018-097485-A-I00) and CIBERINF grants.